Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients

Li, Wen; Bi, Ziran; Wu, Jiawei; Xu, Dehong; Pang, Lulian; Jing, Yanyan; Yin, Xiangxiang; Huang, Cheng

doi:10.3389/fonc.2022.772102

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depression has been identified as a prognostic factor for the survival rate of NSCLC ( Andersen et al, 2023 ). Li et al analyzed NSCLC patients with depression and found that the group with depression had a lower PFS compared to the group without depression ( Li et al, 2022b ). There were statistically significant differences in ORR and DCR between the two groups, indicating that depression can affect the efficacy of chemotherapy combined with immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

Liu,

Lei,

Guo

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Recent studies have revealed that sarcopenia can adversely affect the efficacy of PD-1 inhibitors in the treatment of non-small cell lung cancer (NSCLC). PD-1 inhibitors are immune checkpoint inhibitors widely used in the treatment of various cancers. However, NSCLC patients may have poorer outcomes when receiving PD-1 inhibitor treatment, and sarcopenia may affect the efficacy of PD-1 inhibitors through immune and metabolic mechanisms. In this article, we summarize the reported negative impact of sarcopenia on the effectiveness of PD-1 inhibitors in the treatment of NSCLC in recent years. Based on existing research results, we analyze the possible mechanisms by which sarcopenia affects the efficacy of PD-1 inhibitors and discuss possible strategies to address this issue. This could help to understand the impact of sarcopenia on the treatment of PD-1 inhibitors and provide more accurate expectations of treatment outcomes for clinicians and patients. Additionally, we present tailored intervention strategies for sarcopenic patients undergoing PD-1 inhibitor therapy, aiming to optimize treatment efficacy and enhance patient quality of life. Nevertheless, further research is warranted to elucidate the mechanisms through which sarcopenia impacts PD-1 inhibitors and to identify more efficacious intervention approaches for improving the effectiveness of PD-1 inhibitor treatment in sarcopenic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

Liu,

Lei,

Guo

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Baduanjin exercise for negative emotion of patients undergoing chemotherapy: a systematic review and meta-analysis

He,

Zhang,

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Güven,

Thong,

Arndt

2024

J Cancer Surviv

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) have become a central part of cancer care. However, the survivorship outcomes in patients treated with ICIs are understudied. Therefore, we conducted a scoping review to evaluate the current status of the field and to establish research gaps regarding survivorship outcomes with ICIs in real-life cohorts. Methods We used the Web of Science, PubMed, and Embase databases to systematically filter published studies with real-life cohorts from January 1, 2010, until October 19, 2022. Studies evaluating at least one survivorship outcome in ICI-treated patients were included. Results A total of 39 papers were included. Quality of life (QoL) (n = 23), toxicity burden (n = 16), and psychosocial issues (n = 9) were the most frequently evaluated survivorship outcomes. Anti-PD-1/PD-L1 monotherapy and a response to treatment were associated with better QoL. In addition, the ICIs were associated with grade 3 or higher immune-related adverse events (irAEs) in 10–15% and late/long-term irAEs in 20–30% of the survivors. Regarding psychosocial problems, over 30% of survivors showed evidence of anxiety and depression, and 30–40% of survivors reported neurocognitive impairments. Conclusion The survivors treated with ICIs have impairments in most survivorship domains. Further research is needed to gather data on the understudied survivorship outcomes like late and long-term effects, fertility, financial toxicity, and return to work in survivors treated with ICIs. Implications for Cancer Survivors Available evidence demonstrates that a significant portion of survivors treated with ICIs have a significant toxicity burden, lower QoL than the general population, and a high rate of psychosocial problems.

show abstract

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients

Cited by 3 publications

References 34 publications

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

Baduanjin exercise for negative emotion of patients undergoing chemotherapy: a systematic review and meta-analysis

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Contact Info

Product

Resources

About